Krystal Biotech, Inc. (KRYS) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
58.23
+16% vs avg
5yr avg: 50.39
30Y Low41.1·High59.7
P/FCF
↓
54.31
↑+39% vs avg
5yr avg: 39.09
30Y Low39.1·High39.1
P/B Ratio
↑
8.55
↑+95% vs avg
5yr avg: 4.38
30Y Low1.1·High6.1
ROE
↑
18.9%
↓+1058% vs avg
5yr avg: -2.0%
30Y Low-398%·High19%
Debt/EBITDA
↓
0.06
↓-29% vs avg
5yr avg: 0.08
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KRYS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Krystal Biotech, Inc. trades at 50.9x earnings, 62% below its 5-year average of 135.5x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 130%. On a free-cash-flow basis, the stock trades at 54.3x P/FCF, 39% above the 5-year average of 39.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.3B | $7.4B | $4.7B | $3.4B | $2.0B | $1.6B | $1.1B | $881M | $233M | $56M | — |
| Enterprise Value | $9.8B | $6.9B | $4.3B | $3.1B | $1.9B | $1.2B | $871M | $696M | $129M | $7M | — |
| P/E Ratio → | 50.89 | 36.04 | 52.22 | 318.10 | — | — | — | — | — | — | — |
| P/S Ratio | 26.37 | 18.98 | 16.04 | 67.91 | — | — | — | — | 226.68 | — | — |
| P/B Ratio | 8.55 | 6.05 | 4.92 | 4.42 | 3.87 | 2.62 | 3.86 | 4.34 | 2.06 | 1.14 | — |
| P/FCF | 54.31 | 39.09 | 39.09 | — | — | — | — | — | — | — | — |
| P/OCF | 51.08 | 36.76 | 37.75 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KRYS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Krystal Biotech, Inc.'s enterprise value stands at 58.2x EBITDA, 16% above its 5-year average of 50.4x. The Healthcare sector median is 14.2x, placing the stock at a 310% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 17.72 | 14.88 | 61.00 | — | — | — | — | 125.74 | — | — |
| EV / EBITDA | 58.23 | 41.09 | 59.68 | — | — | — | — | — | — | — | — |
| EV / EBIT | 60.60 | 42.76 | 41.88 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 36.51 | 36.26 | — | — | — | — | — | — | — | — |
KRYS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Krystal Biotech, Inc. earns an operating margin of 41.5%. Operating margins have expanded from -216.4% to 41.5% over the past 3 years, signaling improving operational efficiency. ROE of 18.9% indicates solid capital efficiency. ROIC of 18.0% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.6% | 92.6% | 93.1% | 93.9% | — | — | — | — | 86.3% | — | — |
| Operating Margin | 41.5% | 41.5% | 22.6% | -216.4% | — | — | — | — | -1160.3% | — | — |
| Net Profit Margin | 52.6% | 52.6% | 30.7% | 21.6% | — | — | — | — | -1060.3% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.9% | 18.9% | 10.3% | 1.7% | -25.1% | -15.7% | -13.0% | -12.1% | -13.4% | -31.8% | -397.9% |
| ROA | 17.1% | 17.1% | 9.5% | 1.6% | -23.6% | -14.8% | -12.4% | -11.7% | -13.1% | -30.3% | -52.7% |
| ROIC | 18.0% | 18.0% | 9.5% | -20.6% | -34.6% | -34.6% | -91.6% | -117.4% | -189.4% | -7780.4% | — |
| ROCE | 14.8% | 14.8% | 7.6% | -16.7% | -25.7% | -15.2% | -13.2% | -13.8% | -14.6% | -18.5% | -53.4% |
KRYS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Krystal Biotech, Inc. carries a Debt/EBITDA ratio of 0.1x, which is very conservative (98% below the sector average of 3.2x). The company holds a net cash position — cash of $496M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.04 | 0.02 | — | — | 6.38 |
| Debt / EBITDA | 0.06 | 0.06 | 0.10 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -0.36 | -0.45 | -0.29 | -0.56 | -0.88 | -0.91 | -0.92 | -1.00 | -0.28 |
| Net Debt / EBITDA | -2.90 | -2.90 | -4.66 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.58 | -2.83 | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -45.63 | — | — | -10.60 | -1.48 | -163.29 |
Net cash position: cash ($496M) exceeds total debt ($9M)
KRYS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Krystal Biotech, Inc.'s current ratio of 9.95x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 9.56x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 17.76x to 9.95x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.95 | 9.95 | 7.28 | 17.76 | 13.30 | 17.18 | 17.80 | 58.88 | 43.39 | 77.99 | 50.44 |
| Quick Ratio | 9.56 | 9.56 | 7.02 | 17.55 | 13.30 | 17.18 | 17.80 | 58.88 | 43.39 | 77.99 | 50.44 |
| Cash Ratio | 8.04 | 8.04 | 5.86 | 16.08 | 13.14 | 17.02 | 17.56 | 58.22 | 43.05 | 77.49 | 44.72 |
| Asset Turnover | — | 0.29 | 0.28 | 0.06 | — | — | — | — | 0.01 | — | — |
| Inventory Turnover | 0.71 | 0.71 | 0.76 | 0.44 | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 119.52 | 131.60 | 302.66 | — | — | — | — | — | — | — |
KRYS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Krystal Biotech, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 2.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.0% | 2.8% | 1.9% | 0.3% | — | — | — | — | — | — | — |
| FCF Yield | 1.8% | 2.6% | 2.6% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $30M | $30M | $28M | $25M | $22M | $19M | $16M | $11M | $5M | $4M |
Peer Comparison
Compare KRYS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KRYSYou | $10B | 50.9 | 58.2 | 54.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $7B | 10.2 | 6.8 | 9.3 | 95.9% | 49.5% | — | — | 0.5 |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SGMO | $75M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into KRYS consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
KRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
What is Krystal Biotech, Inc.'s P/E ratio?
Krystal Biotech, Inc.'s current P/E ratio is 50.9x. The historical average is 44.1x. This places it at the 50th percentile of its historical range.
What is Krystal Biotech, Inc.'s EV/EBITDA?
Krystal Biotech, Inc.'s current EV/EBITDA is 58.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 50.4x.
What is Krystal Biotech, Inc.'s ROE?
Krystal Biotech, Inc.'s return on equity (ROE) is 18.9%. The historical average is -47.8%.
Is KRYS stock overvalued?
Based on historical data, Krystal Biotech, Inc. is trading at a P/E of 50.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Krystal Biotech, Inc.'s profit margins?
Krystal Biotech, Inc. has 92.6% gross margin and 41.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Krystal Biotech, Inc. have?
Krystal Biotech, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.